Content
All Posts > Content under Pharma/Biotech
3 Of The Best & Worst Performing Drug Stocks Of Q1
Article By:
Arpita Dutt
Read
Thursday, April 6, 2017 11:37 AM EDT
Pharma and biotech stocks have been showing signs of recovery this year. The sector started the year on a strong note with the Nasdaq Biotechnology Index and the NYSE ARCA Pharmaceutical Index gaining 10.7% and 5.7%, in the first quarter of 2017.
Yeliva Granted Orphan Drug Designation In Cholangiocarcinoma
Article By:
Jason Napodano
Read
Tuesday, April 4, 2017 3:58 PM EDT
I ultimately believe that RedHill will look to partner Yeliva for Phase 3 development, and RedHill is certainly well-funded today with $66 million on hand as of December 2016, but every bit of financial assistance helps.
In this article: RDHL
Paratek Pharmaceuticals Scores Clean Sweep In Pivotal Test Of New Drug For Treating CABP - Stock Jumps Dramatically
Article By:
Lorimer Wilson
Read
Tuesday, April 4, 2017 11:34 AM EDT
Paratek Pharmaceuticals, Inc. shares shot up 36% in pre-market trading on Tuesday as investors reacted to the Boston biotech’s proclamation of a clean sweep for its pivotal test of its new antibiotic omadacycline.
In this article: PRTK
Teva Pharmaceutical Receives FDA Approval For A Deuterated Drug (A First) For The Treatment Of Huntington’s Chorea
Article By:
Lorimer Wilson
Read
Tuesday, April 4, 2017 10:05 AM EDT
Teva Pharmaceutical Industries Limited has received FDA approval for deutetrabenazine - the first FDA approval in the world of deuterated drugs - for the treatment of Huntington’s chorea.
In this article: TEVA
Zymeworks Inc. Files Registration Statement For Proposed IPO
Article By:
Lorimer Wilson
Read
Monday, April 3, 2017 3:13 PM EDT
Zymeworks Inc. of Vancouver, British Columbia, has been blitzing its way through a series of partnerships and expansion projects focused on its bispecific antibodies and armed ADCs...[which] will now depend on raising at least $75 million in an IPO.
When Investing In Health Care Focus On The Merits Of Individual Companies Rather Than The Entire Sector - Here's Why
Article By:
Lorimer Wilson
Read
Monday, April 3, 2017 2:35 PM EDT
An appropriate strategy when buying health care stocks is to focus on the merits of individual stocks rather than the entire sector. We see opportunities in biotech, medical devices, managed care & big pharma with promising drug pipelines.
Sucampo Pharmaceuticals, Inc. Buying Rare Disease Player "Vtesse" For $200M
Article By:
Lorimer Wilson
Read
Monday, April 3, 2017 1:22 PM EDT
Sucampo Pharmaceuticals is buying Vtesse for $200 million. In doing so, Sucampo is picking up a late-stage asset, VTS-270, now in a global pivotal trial, with a readout expected in mid-2018. Sucampo is confidently projecting a market launch in 2019.
In this article: SCMP
Roche, Prothena Off To PhII With Their Disease-Modifying Parkinson’s Drug
Article By:
Lorimer Wilson
Read
Monday, April 3, 2017 5:41 AM EDT
Prothena turned up at the big Alzheimer’s/Parkinson’s conference in Vienna this weekend and presented early-stage data showing how its Roche-partnered drug PRX002/RG7935 can flush out toxic clusters of alpha-synuclein in Parkinson’s patients.
Three Ways Out Of The Penalty Box For The S&P
MAT2501 Phase 1 Data Look Good, Shares Look Attractive
Article By:
Jason Napodano
Read
Wednesday, March 29, 2017 10:09 AM EDT
Matinas Biopharma's stock is cheap and I can easily see Matinas getting taken out at much higher levels - like most anti-infectant companies do - perhaps after the pipeline matures a bit.
In this article: MTNB
Will Healthcare And Biotech Resume Market Leadership?
Article By:
Justin Smyth
Read
Wednesday, March 29, 2017 5:37 AM EDT
Biotech ETFs XBI and IBB are outperforming so far this year. It’s not too surprising if you use Stage Analysis since we know that bear markets are authors of bull markets, and biotech was one of the worst performing sectors of 2016.
These 5 Stocks Expected To Exceed Canada Goose Holdings' 83% YoY EPS Growth - That's Impressive!
Article By:
Lorimer Wilson
Read
Tuesday, March 28, 2017 4:30 PM EDT
The Canada Goose Holdings IPO garnered attention from investors with Y/Y EPS growth of over 83%. Be that as it may, today we highlight 5 stocks that are expected to have greater 2017 earnings per share growth than Canada Goose, year-over-year.
Novartis-Backed Ionis Subsidiary Akcea Maps A $100M IPO As It Steers A Lead Drug To Regulators
Article By:
Lorimer Wilson
Read
Monday, March 27, 2017 6:16 PM EDT
Ionis Pharmaceuticals, Inc. subsidiary Akcea — a specialist in lipid disorders — is shooting for a $100 million IPO, with Novartis coming in to support the move with an extra $50 million to purchase a growing equity stake.